Togo introduced monovalent rotavirus vaccine starting 19 June 2014. We compared all-cause acute gastroenteritis (AGE) hospitalizations and rotavirus-associated hospitalizations during the prevaccine period (July 2008-June 2014) to 1 year after vaccine introduction (July 2014-June 2015). The proportion of children with AGE who tested positive for rotavirus declined from 53% (645/1223) in prevaccine years to 36% (68/187) in the postvaccine year (P< .01). The decline only occurred in children <1 year of age who were eligible for vaccination and was greatest during the rotavirus season months, supporting that it was associated with vaccine implementation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/civ1182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda.
Vaccine
January 2025
Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address:
Background: The underlying causes for lower rotavirus vaccine effectiveness (VE) in high-child-mortality settings are not well understood. Uganda introduced the human monovalent G1P[8] rotavirus vaccine (Rotarix) in June 2018. We determined the effectiveness of Rotarix against rotavirus diarrhea requiring hospital care among Ugandan children.
View Article and Find Full Text PDFAccounting for local incidence when estimating rotavirus vaccine efficacy among countries: a pooled analysis of monovalent rotavirus vaccine trials.
Am J Epidemiol
December 2024
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Rotavirus vaccine appears to perform sub-optimally in countries with higher rotavirus burden. We hypothesized that differences in the magnitude of rotavirus exposures may bias vaccine efficacy (VE) estimates, so true differences in country-specific rotavirus VE would be exaggerated without accommodating differences in exposure. We estimated VE against any-severity and severe rotavirus gastroenteritis (RVGE) using Poisson regression models fit to pooled individual-level data from Phase II and III monovalent rotavirus vaccine trials conducted between 2000 and 2012.
View Article and Find Full Text PDFThe Apparent Lack of the Risk of Intussusception Immediately After Rotavirus Vaccination Among Japanese Infants.
Viruses
November 2024
Department of Pediatrics, Akita University Graduate School of Medicine, Akita-shi 010-8543, Japan.
Rotavirus vaccines carry a small risk of intussusception mainly 1-7 days after vaccination in the United States of America, Europe, Australia, and Latin America where the background rate of intussusception is relatively low. Such risks are undetectable in Africa and India where the background rate is the lowest. Because few studies were carried out in high-background-rate countries such as Japan, we examined how intussusception occurred in infants living in Akita prefecture, Japan, while the vaccines were sold in the private market.
View Article and Find Full Text PDFCharacteristics of maternal antibodies transferred to foals raised through maternal equine rotavirus A vaccination.
Vet Microbiol
December 2024
Department of Veterinary Science, Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY, USA. Electronic address:
Equine rotavirus A (ERVA) can cause foal diarrhoea and the most common ERVA genotypes are G3P[12] and G14P[12]. Since the introduction of a monovalent killed G3P[12] vaccine, infection in neonates has decreased. We aimed to determine the dynamics and longevity of maternally derived anti-G3P[12] neutralizing antibodies (NAbs) in foals and what, if any, cross-reactivity exists between maternally derived NAbs against G14P[12].
View Article and Find Full Text PDFVP8 Mosaic Nanoparticles Elicit Cross-Neutralizing Immune Responses and Provide Protection Against Heterotypic Rotavirus Challenge in Mice.
ACS Nano
November 2024
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, Xiamen University, Xiamen 361102, China.
Article Synopsis
- Group A rotaviruses (RVA) are a leading cause of diarrhea in children under 5, but vaccination has reduced instances and deaths.
- Recent challenges include decreasing efficacy of current rotavirus vaccines and new virus strains, highlighting the need for improved vaccines.
- This study explores using nanoparticles to enhance the immune response to rotavirus proteins, showing promise for developing a next-generation broad-spectrum vaccine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!